KEYMED BIO-B (02162) has announced that its board of directors resolved on August 19, 2026, to propose the issuance of ordinary shares denominated and traded in Renminbi, with a planned listing on the Shanghai Stock Exchange's Science and Technology Innovation Board (STAR Market).

The proposed RMB share issuance remains subject to and conditional upon several factors, including prevailing market conditions, further board approval, shareholder approval at the company's general meeting, and the acquisition of necessary regulatory approvals.

As of the date of this announcement, aside from the preliminary framework of the proposed RMB share issuance and the information separately disclosed in this announcement, the board has no other plans concerning the proposed issuance, nor has any application been submitted to relevant regulatory authorities in connection with it.